|
Basic Characteristics of Mutations
|
|
Mutation Site
|
E484K |
|
Mutation Site Sentence
|
The receptor-binding domain mutations provide tighter ACE2 binding and widespread escape from monoclonal antibody neutralization largely driven by E484K; although K417N and N501Y act together against some important antibody classes. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
RBD |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
B.1.351 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
UK |
|
Literature Information
|
|
PMID
|
33730597
|
|
Title
|
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
|
|
Author
|
Zhou D,Dejnirattisai W,Supasa P,Liu C,Mentzer AJ,Ginn HM,Zhao Y,Duyvesteyn HME,Tuekprakhon A,Nutalai R,Wang B,Paesen GC,Lopez-Camacho C,Slon-Campos J,Hallis B,Coombes N,Bewley K,Charlton S,Walter TS,Skelly D,Lumley SF,Dold C,Levin R,Dong T,Pollard AJ,Knight JC,Crook D,Lambe T,Clutterbuck E,Bibi S,Flaxman A,Bittaye M,Belij-Rammerstorfer S,Gilbert S,James W,Carroll MW,Klenerman P,Barnes E,Dunachie SJ,Fry EE,Mongkolsapaya J,Ren J,Stuart DI,Screaton GR
|
|
Journal
|
Cell
|
|
Journal Info
|
2021 Apr 29;184(9):2348-2361
|
|
Abstract
|
The race to produce vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began when the first sequence was published, and this forms the basis for vaccines currently deployed globally. Independent lineages of SARS-CoV-2 have recently been reported: UK, B.1.1.7; South Africa, B.1.351; and Brazil, P.1. These variants have multiple changes in the immunodominant spike protein that facilitates viral cell entry via the angiotensin-converting enzyme-2 (ACE2) receptor. Mutations in the receptor recognition site on the spike are of great concern for their potential for immune escape. Here, we describe a structure-function analysis of B.1.351 using a large cohort of convalescent and vaccinee serum samples. The receptor-binding domain mutations provide tighter ACE2 binding and widespread escape from monoclonal antibody neutralization largely driven by E484K, although K417N and N501Y act together against some important antibody classes. In a number of cases, it would appear that convalescent and some vaccine serum offers limited protection against this variant.
|
|
Sequence Data
|
-
|
|
|